Imunon Inc. has published a document detailing a Phase I/II study on the safety and efficacy of the investigational product IMNN-001, in combination with standard of care treatment, for patients newly diagnosed with advanced epithelial ovarian cancer. The document provides updated survival analysis from the OVATION-2 trial, highlighting the study's primary and secondary endpoints, including safety, progression-free survival, overall survival, and response rates. The full document can be accessed through the link below.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。